Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
The ATNF news page on Stock Titan provides an archive of announcements and press releases related to 180 Life Sciences Corp. and its transformation into the ETHZilla brand. Readers can follow how the company evolved from an innovative biotechnology business into a firm focused on the global iGaming sector and, more recently, on an Ethereum (ETH) treasury strategy.
Company news covers several distinct themes. First, there are updates on private placements and financing transactions, including a large PIPE offering and a convertible note issuance that the company has stated are intended to fund the rapid accumulation of Ether and related yield-bearing assets. These items often detail the structure of the financings and the company’s intended use of proceeds, such as ETH purchases, support for iGaming operations, and efforts to monetize legacy biotech intellectual property.
Second, the news flow includes treasury and ETH holdings updates, where the company reports the amount of ETH it holds, the approximate value of those holdings, and the role of Electric Capital as external asset manager for its on-chain yield generation program. These releases provide insight into how the ETH treasury strategy is being implemented over time.
Third, investors can review corporate strategy and governance announcements, including the planned rebranding to ETHZilla Corporation, changes in ticker symbols, board appointments, and steps taken to regain or maintain compliance with Nasdaq listing requirements. Additional releases describe the company’s pivot into iGaming, its proprietary Technology Gaming Platform, and ongoing development of gaming initiatives.
Finally, the archive includes biotechnology IP and patent updates, such as notices of allowance and granted patents related to post-operative cognitive decline, neuroinflammation, and fibrotic disorders. Together, these news items document the company’s multi-stage evolution and provide context for both its historical biotech activities and its current focus on digital assets and gaming.
ETHZilla Corporation (NASDAQ: ETHZ), formerly 180 Life Sciences Corp. (NASDAQ: ATNF), announced a major rebranding and strategic shift to focus on Ethereum treasury operations. The company's stock will begin trading under the new ticker ETHZ on August 18, 2025.
The company has successfully raised $565 million through private placements, including a $425 million PIPE and $156.25 million convertible note offering. ETHZilla has already accumulated 94,675 ETH at an average price of $3,902.20, currently valued at approximately $419 million, with an additional $187 million in cash equivalents.
Electric Capital will serve as the external asset manager, implementing an on-chain yield generation program combining staking, lending, and liquidity provisioning. The private placement attracted over 60 institutional and crypto-native investors, including prominent Ethereum ecosystem leaders.
180 Life Sciences (NASDAQ:ATNF), operating as ETHZilla, has announced significant cryptocurrency holdings of 82,186 Ethereum (ETH) acquired at an average price of $3,806.71, currently valued at approximately $349 million. The company also maintains $238 million in USD cash equivalents.
Following a recent PIPE transaction, ETHZilla has implemented its strategy as an Ethereum treasury vehicle. The company plans to generate yield through staking arrangements with Electric Capital, their external asset manager. With 154.032 million shares outstanding, ETHZilla aims to create shareholder value through on-chain yield generation programs.
180 Life Sciences (NASDAQ: ATNF) has successfully closed a private offering of $156 million in senior secured convertible notes due 2028 to an institutional investor. The notes will begin accruing 4% annual interest after six months and are convertible into common stock at $3.445 per share, subject to potential downward adjustment after nine months.
This offering follows the company's recent $425 million private placement. The proceeds will primarily be used to expand the company's Ethereum (ETH) holdings as part of its treasury strategy. The notes include provisions for company-mandated conversion after six months, subject to certain restrictions.
Clear Street LLC served as financial advisor and exclusive placement agent, with The Loev Law Firm, PC and Reed Smith LLP acting as legal advisors.
180 Life Sciences (NASDAQ: ATNF) has successfully closed a $425 million private placement to implement its Ethereum treasury strategy. The PIPE transaction, priced at $2.65 per share, was led by Electric Capital and Harbour Island, with participation from prominent crypto investors including Borderless Capital and Polychain Capital.
The company plans to use the proceeds primarily to purchase Ethereum (ETH) and implement a yield generation program managed by Electric Capital. The program aims to outperform traditional ETH staking through a combination of staking, lending, and liquidity provisioning. Additionally, the company announced significant governance updates, including the appointment of McAndrew Rudisill as Board Chairman and new independent directors.
The company may further raise up to $150 million through fixed income securities following the PIPE completion.
180 Life Sciences (NASDAQ: ATNF) has announced a significant strategic pivot with a $425 million private placement to establish an Ethereum treasury reserve. The company plans to rebrand as ETHZilla Corporation and will primarily use the proceeds to purchase Ether (ETH). The PIPE transaction, expected to close around August 1, 2025, involves over 60 institutional and crypto-native investors.
Electric Capital will serve as the external asset manager, implementing an on-chain yield generation program designed to outperform traditional ETH staking. The company also plans to launch with Etherealize as a key partner and establish a DeFi Council comprising ecosystem leaders to guide treasury management. Additionally, the company has approval to sell up to $150 million in debt securities following the PIPE closing.
180 Life Sciences Corp. (NASDAQ:ATNF), a biotechnology company transitioning to the iGaming sector, has announced significant enhancements to its legacy intellectual property portfolio through two new patent developments.
The first development is the granting of U.S. Patent No. 12,325,744 B2 by the USPTO, focused on methods for preventing post-operative cognitive decline. This patent, owned by The Kennedy Trust and licensed to 180, covers treatments for reducing cognitive impairment following planned inflammatory triggers like surgery or chemotherapy.
The second development involves a Notice of Allowance from the Canadian Intellectual Property Office for a patent application covering the treatment of localized fibrotic disorders using an IL-33 antagonist. This patent, owned solely by 180, specifically targets conditions like Dupuytren's Disease and Frozen Shoulder.
180 Life Sciences Corp. (NASDAQ:ATNF) has received a Notice of Allowance from the USPTO for a patent application covering a novel method to prevent Post-Operative Cognitive Dysfunction (POCD). The patent focuses on reducing POCD by administering anti-Human tumor necrosis factor (TNF) Alpha monoclonal antibody during surgical procedures.
POCD is a significant complication affecting elderly patients undergoing surgery, manifesting as memory loss, concentration impairment, delirium, and other cognitive issues. The company's method targets inflammatory pathways via ATNF therapy to minimize neuroinflammation post-surgery.
Notably, while this patent strengthens the company's legacy biotechnology portfolio, 180 Life Sciences is currently transitioning its focus to the global iGaming sector, developing online casino and entertainment businesses through its Technology Gaming Platform.
180 Life Sciences has announced a significant share repurchase agreement with Elray Resources and Luxor Capital. The company will acquire and cancel 1,318,000 shares (23.1% of outstanding shares) for $1 million through a structured payment plan: $350,000 directly to Elray and $650,000 to Luxor from future capital raises by April 2026.
The deal includes a Voting Agreement requiring Elray to vote remaining shares according to the Board's recommendations until April 2026, with CEO Blair Jordan holding irrevocable proxy. The agreement features mutual releases, confidentiality obligations, and indemnity protection.
This strategic move aims to reduce dilution and simplify the company's capital structure while preserving cash liquidity. The company plans to focus on monetizing its Technology Gaming Platform through potential online casino acquisitions.
180 Life Sciences Corp. (NASDAQ:ATNF), a biotech company transitioning to international entertainment and iGaming, has announced a $2.9 million registered direct offering and concurrent private placement. The company will sell 1,200,000 common stock shares at $2.41 per share, along with unregistered warrants for an additional 1,200,000 shares. The warrants, exercisable immediately at $2.28 per share, will expire after five and a half years. Maxim Group is serving as the sole placement agent, with the offering expected to close around December 30, 2024.
180 Life Sciences Corp has announced its return to full compliance with Nasdaq Listing Rule 5605(c)(2) following the appointment of Stephen Shoemaker as an independent director and audit committee member. This appointment resolves all previously announced deficiencies in Nasdaq's continued listing requirements.
Interim CEO Blair Jordan confirmed that the company is now focusing on its strategic pivot into the iGaming sector, highlighting the potential of their recently acquired Technology Gaming Platform, particularly in relation to cryptocurrency adoption. The management team and board are aligned on leveraging emerging technologies and market trends in the iGaming industry.